|
Report Date : |
27.04.2013 |
IDENTIFICATION DETAILS
|
Name : |
ELI LILLY JAPAN KK |
|
|
|
|
Registered Office : |
Sannomiya Plaza Bldg, 7-1-5 Isogamidori Chuoku Kobe 651-0086 |
|
|
|
|
Country : |
Japan |
|
|
|
|
Financials (as on) : |
31.12.2012 |
|
|
|
|
Date of Incorporation : |
November 1975 |
|
|
|
|
Com. Reg. No.: |
1400-01-012176 (Kobe-Chuoku) |
|
|
|
|
Legal Form : |
Limited Company (Kabushiki Kaisha) |
|
|
|
|
Line of Business : |
Manufacturer processing of pharmaceutical drugs |
|
|
|
|
No. of Employees : |
2,400 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Good |
|
Payment Behaviour : |
Regular |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2013
|
Country Name |
Previous Rating (31.12.2012) |
Current Rating (31.03.2013) |
|
Japan |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
JAPAN - ECONOMIC OVERVIEW
In the years following World War II, government-industry
cooperation, a strong work ethic, mastery of high technology, and a
comparatively small defense allocation (1% of GDP) helped Japan develop a
technologically advanced economy. Two notable characteristics of the post-war
economy were the close interlocking structures of manufacturers, suppliers, and
distributors, known as keiretsu, and the guarantee of lifetime employment for a
substantial portion of the urban labor force. Both features are now eroding
under the dual pressures of global competition and domestic demographic change.
Japan's industrial sector is heavily dependent on imported raw materials and
fuels. A small agricultural sector is highly subsidized and protected, with
crop yields among the highest in the world. While self-sufficient in rice
production, Japan imports about 60% of its food on a caloric basis. For three
decades, overall real economic growth had been spectacular - a 10% average in
the 1960s, a 5% average in the 1970s, and a 4% average in the 1980s. Growth
slowed markedly in the 1990s, averaging just 1.7%, largely because of the after
effects of inefficient investment and an asset price bubble in the late 1980s
that required a protracted period of time for firms to reduce excess debt,
capital, and labor. Modest economic growth continued after 2000, but the
economy has fallen into recession three times since 2008. A sharp downturn in
business investment and global demand for Japan's exports in late 2008 pushed
Japan into recession. Government stimulus spending helped the economy recover
in late 2009 and 2010, but the economy contracted again in 2011 as the massive
9.0 magnitude earthquake and the ensuing tsunami in March disrupted
manufacturing. The economy has largely recovered in the two years since the
disaster, but reconstruction in the Tohoku region has been uneven.
Newly-elected Prime Minister Shinzo ABE has declared the economy his
government's top priority; he has pledged to reconsider his predecessor's plan
to permanently close nuclear power plants and is pursuing an economic
revitalization agenda of fiscal stimulus and regulatory reform and has said he
will press the Bank of Japan to loosen monetary policy. Measured on a
purchasing power parity (PPP) basis that adjusts for price differences, Japan
in 2012 stood as the fourth-largest economy in the world after second-place
China, which surpassed Japan in 2001, and third-place India, which edged out
Japan in 2012. The new government will continue a longstanding debate on restructuring
the economy and reining in Japan's huge government debt, which exceeds 200% of
GDP. Persistent deflation, reliance on exports to drive growth, and an aging
and shrinking population are other major long-term challenges for the economy.
Source
: CIA
ELI LILLY JAPAN KK
REGD NAME: Nihon
Eli Lilly KK
MAIN OFFICE: Sannomiya
Plaza Bldg, 7-1-5 Isogamidori Chuoku Kobe 651-0086 JAPAN
Tel:
078-242-9000 Fax: 078-242-9502
URL: http//:www.lilly.co.jp
E-mail: (thru the URL)
Mfg, processing of
pharmaceutical drugs
Tokyo, Nagoya,
Osaka, Sapporo, Niigata, Chiba, Kanazawa, other (Tot 24)
Kobe (Laboratory
is attached)
ALFONSO G ZULUETA,
PRES
Yen Amount: In million Yen, unless otherwise stated
FINANCES FAIR A/SALES Yen 175,740 M
PAYMENTS REGULAR CAPITAL Yen
12,773 M
TREND STEADY WORTH Yen
42,980 M
STARTED 1975 EMPLOYES 2,400
MFR OF
PHARMACEUTICAL DRUGS.
FINANCIAL SITUATION CONSIDERED FAIR TO GOOD
AND RESPONSIBLE FOR ORDINARY BUSINESS ENGAGEMENTS
The subject company was
established originally in 1965 as JV with Shionogi & Co Ltd, major
pharmaceutical mfr, Osaka, and Eli Lilly USA, and subsequently in 1975 founded
the independent entity as captioned.
This firm specializes in mfg pharmaceutical drugs for: central nerve,
metabolic, oncology, osteoporosis, endocrine system, and animal drugs.
The sales volume for Dec/2012
fiscal term amounted to Yen 175,740 million, a 10% up from Yen 159,436 million
in the previous term. Drugs particularly
for osteoporosis and endocrine systems were in robust demand, the firm says. The recurring profit was posted at Yen 13,472
million and the net profit at Yen 6,616 million, respectively, compared with
Yen 619,788 million recurring profit and Yen 11,387 million net profit,
respectively, a year ago. .
For the current
term ending Dec 2013 the recurring profit is projected at Yen 15,000 million
and the net profit at Yen 6,800 million, respectively, on an 8% rise in
turnover, to Yen 190,000 million.
The financial situation
is considered FAIR to GOOD and responsible for ORDINARY business
engagements.
Date Registered: Nov
1975
Regd No.;
1400-01-012176 (Kobe-Chuoku)
Legal Status: Limited Company (Kabushiki Kaisha)
Authorized: 25,545,000 shares
Issued:
25,545,000 shares
Sum: Yen 12,773 million
Major shareholders (%): Eli Lilly USA
(100)
Nothing
detrimental is known as to the commercial morality of executives.
Activities: Manufactures
pharmaceutical drugs for: central nerve system, endocrine system, metabolic,
osteoporosis, oncology, animal drugs, other (--100%).
Clients: [Mfrs, wholesalers]
Suzuken Co, Alfresa Corp, other
No. of accounts:
500
Domestic areas of
activities: Nationwide
Suppliers: [Mfrs,
wholesalers] Supplied from Eli Lilly and group firms.
Payment record: Regular
Location: Business area in
Kobe. Office premises at the caption
address are leased and maintained satisfactorily.
Bank References:
City Bank (H/O)
Relations:
Satisfactory
(In Million Yen)
|
Terms Ending: |
31/12/2013 |
31/12/2012 |
31/12/2011 |
31/12/2010 |
|
|
Annual
Sales |
|
190,000 |
175,740 |
159,436 |
134,471 |
|
Recur.
Profit |
|
15,000 |
13,742 |
19,788 |
10,001 |
|
Net
Profit |
|
6,800 |
6,616 |
11,387 |
5,410 |
|
Total
Assets |
|
|
83,976 |
75,363 |
72,107 |
|
Current
Assets |
|
|
71,526 |
62,680 |
58,962 |
|
Current
Liabs |
|
|
30,534 |
23,294 |
32,271 |
|
Net
Worth |
|
|
42,980 |
41,064 |
29,677 |
|
Capital,
Paid-Up |
|
|
12,773 |
12,773 |
12,773 |
|
Div.P.Share(¥) |
|
|
0.00 |
0.00 |
0.00 |
|
<Analytical Data> |
(%) |
(%) |
(%) |
(%) |
|
|
S.Growth Rate |
8.11 |
10.23 |
18.57 |
71.08 |
|
|
Current Ratio |
|
.. |
234.25 |
269.08 |
182.71 |
|
N.Worth Ratio |
.. |
51.18 |
54.49 |
41.16 |
|
|
R.Profit/Sales |
|
7.89 |
7.82 |
12.41 |
7.44 |
|
N.Profit/Sales |
3.58 |
3.76 |
7.14 |
4.02 |
|
|
Return On Equity |
.. |
15.39 |
27.73 |
18.23 |
|
Notes: Forecast
(or estimated) figures for the 31/12/2013 fiscal term.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.54.29 |
|
|
1 |
Rs.83.88 |
|
Euro |
1 |
Rs.70.67 |
INFORMATION DETAILS
|
Report
Prepared by : |
PRL |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.